MedTrace Logo

Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients

NCT02619747 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-10-06

No results posted yet for this study

Summary

Multi-centre, randomised, open-label, placebo-controlled, two-period crossover study of 4 hour pH monitoring following a refluxogenic meal and drink.

Conditions

  • Gastro-esophageal Reflux Disease (GERD)

Interventions

DRUG

Compound Sodium Alginate Oral Suspension sachet

DRUG

Matched placebo

Sponsors & Collaborators

  • Reckitt Benckiser Healthcare (UK) Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02619747 on ClinicalTrials.gov